Finch Therapeutics Group Stock News

Finch Therapeutics Group, Inc. (NASDAQ: FNCH - Get Free Report) dropped 2.7% during trading on Wednesday. The stock traded as low as $12.50 and last traded at $12.50. Approximately 283 shares traded h

Profitability This table compares Finch Therapeutics Group and Eloxx Pharmaceuticals' net margins, return on equity and return on assets. Net Margins Return on Equity Return on Assets Finch Therapeuti

Risk and Volatility Eloxx Pharmaceuticals has a beta of -1720.35, suggesting that its share price is 172,135% less volatile than the S&P 500. Comparatively, Finch Therapeutics Group has a beta of 1.17

Earnings and Valuation This table compares Finch Therapeutics Group and ZIVO Bioscience"s top-line revenue, earnings per share and valuation. Gross Revenue Price/Sales Ratio Net Income Earnings Per Sh

ENDI Corp's shares rose significantly, driven by a substantial increase in AUM and a value-unlocking transaction, suggesting further upside potential. Finch Therapeutics awaits a post-trial decision t

BOSTON, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (Nasdaq: FNCH) (“Finch” or the “Company”), a microbiome technology company with a portfolio of intellectual property an

Penny stocks to buy according to analysts. The post 4 Penny Stocks To Buy According To Analysts, Targets Up To 1,650% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.c

Finch Therapeutics Group, Inc. (FNCH) delivered earnings and revenue surprises of -12.50% and 90.80%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead f

Finch Therapeutics Group, Inc. (FNCH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term

SOMERVILLE, Mass., May 09, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging

The FDA, at long last, has lifted a clinical hold on Finch's C. diff program.

Finch Therapeutics (FNCH) stock is rising higher on Friday following news that the FDA has released its clinical hold on CP101. The post Why Is Finch Therapeutics (FNCH) Stock Up 30% Today?

What you need to know about buying penny stocks on April 29th The post Best Penny Stocks to Buy Today? 3 to Watch on April 29th appeared first on Penny Stocks to Buy, Picks, News and Information | Pen

NEW YORK, March 2, 2022 /PRNewswire/ -- PomerantzLLP is investigating claims on behalf of investors of Finch Therapeutics Group, Inc. ("Finch" or the "Company") (NASDAQ: FNCH). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980….

The FDA has issued a clinical hold letter to Finch Therapeutics Group Inc''s (NASDAQ: FNCH ) PRISM4 Phase 3 trial of CP101 in recurrent C. difficile infection (CDI). The Company has paused enrollment in the trial as the FDA has asked for additional information about Finch''s SARS-CoV-2 donor screening protocols. The FDA placed Finch''s investigational new drug application (IND) for CP101 and the IND of its then-contract manufacturer, … Full story available on Benzinga.com